Angiotensin II infusion in COVID-19: An international, multicenter, registry-based study.
Angiotensin II infusion in COVID-19: An international, multicenter, registry-based study.
复制标题
DOI：
10.1002/jmv.27592
复制
发表时间：
2022-05
影响因子：
12.7
通讯作者：
Bellomo, Rinaldo
中科院分区：
文献类型：
--
作者：
Serpa Neto, Ary;Landoni, Giovanni;Ostermann, Marlies;Lumlertgul, Nuttha;Forni, Lui;Alvarez-Belon, Lucas;Trapani, Tony;Alliegro, Patricia, V;Zacharowski, Kai;Wiedenbeck, Carolin;de Backer, Daniel;Bellomo, Rinaldo
为了进一步了解血管紧张素II （ANGII）在冠状病毒传染病2019 （COVID - 19）中的作用，我们开展了一项国际多中心注册研究，以评估COVID - 19患者与未接受ANGII治疗的患者相比使用ANGII的情况。根据年龄、呼吸支持、高血压史、血管紧张素转换酶抑制剂和/或ANGII受体阻滞剂的使用情况以及入院日期，将诊断为COVID - 19并接受ANGII治疗的危重成人患者与未接受ANGII治疗的COVID - 19患者进行匹配。所有结果都是探索性的，包括氧合改善、器官支持持续时间和死亡率。一年内，纳入132例患者（ANGII组65例，对照组67例），患者的基线特征具有可比性。在输注前12小时，ANGII组患者FiO2下降更快，平均动脉压水平保持相似。两组住院死亡率差异无统计学意义（53.8%比40.3%;p = 0.226）。在这种研究设计的局限性内，我们的研究结果证实了先前的观察，即ANGII对血压和FiO2有潜在的积极作用，但对以患者为中心的结局没有影响。在2019冠状病毒感染性疾病患者中，最近在一个非对照病例系列中评估了血管紧张素II （ANGII）对氧合的生理影响。在输注前12小时，ANGII组患者FiO2下降更快，平均动脉压水平保持相似。两组间住院死亡率无统计学差异。
To expand our understanding of the role of angiotensin II (ANGII) in coronavirus infectious disease 2019 (COVID‐19), we conducted an international, multicenter registry study to assess the use of ANGII in patients with COVID‐19 compared to patients not receiving ANGII. Critically ill adult patients who were diagnosed with COVID‐19 and received ANGII were matched with COVID‐19 patients not receiving ANGII according to age, respiratory support, history of hypertension, use of angiotensin‐converting enzyme inhibitors and/or ANGII receptor blocker, and date of admission. All outcomes were exploratory in nature and included improvement in oxygenation, duration of organ support, and mortality. In one year, 132 patients were included (65 in the ANGII group and 67 in the control group), and patients were comparable in baseline characteristics. During the first 12 h of infusion, patients in the ANGII had a faster decrease in FiO2 and maintained similar mean arterial pressure levels. Hospital mortality was not statistically significantly different between the groups (53.8% vs. 40.3%; p = 0.226). Within the limitations of such a study design, our findings confirm previous observations of a potentially positive effect of ANGII on blood pressure and FiO2 but no effect on patient‐centered outcomes. In patients with coronavirus infectious disease 2019, the physiological effect of angiotensin II (ANGII) on oxygenation was recently assessed in an uncontrolled case series. During the first 12 h of infusion, patients in the ANGII had a faster decrease in FiO2 and maintained similar mean arterial pressure levels. Hospital mortality was not statistically significantly different between the groups.
登录
查看更多内容
影响因子：
5.4
作者：
Loader J;Lampa E;Gustafsson S;Cars T;Sundström J
通讯作者：
Sundström J
DOI：
10.1164/rccm.201911-2172oc
发表时间：
2020-11-01
影响因子：
24.7
作者：
Bellomo R;Forni LG;Busse LW;McCurdy MT;Ham KR;Boldt DW;Hästbacka J;Khanna AK;Albertson TE;Tumlin J;Storey K;Handisides D;Tidmarsh GF;Chawla LS;Ostermann M
通讯作者：
Ostermann M
DOI：
10.1016/s2213-2600(21)00214-9
发表时间：
2021-08
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Bauer A;Schreinlechner M;Sappler N;Dolejsi T;Tilg H;Aulinger BA;Weiss G;Bellmann-Weiler R;Adolf C;Wolf D;Pirklbauer M;Graziadei I;Gänzer H;von Bary C;May AE;Wöll E;von Scheidt W;Rassaf T;Duerschmied D;Brenner C;Kääb S;Metzler B;Joannidis M;Kain HU;Kaiser N;Schwinger R;Witzenbichler B;Alber H;Straube F;Hartmann N;Achenbach S;von Bergwelt-Baildon M;von Stülpnagel L;Schoenherr S;Forer L;Embacher-Aichhorn S;Mansmann U;Rizas KD;Massberg S;ACEI-COVID investigators
通讯作者：
ACEI-COVID investigators
影响因子：
9.6
作者：
Wieruszewski, Patrick M.;Wittwer, Erica D.;Barreto, Erin F.
通讯作者：
Barreto, Erin F.
影响因子：
8.8
作者：
Tumlin JA;Murugan R;Deane AM;Ostermann M;Busse LW;Ham KR;Kashani K;Szerlip HM;Prowle JR;Bihorac A;Finkel KW;Zarbock A;Forni LG;Lynch SJ;Jensen J;Kroll S;Chawla LS;Tidmarsh GF;Bellomo R;Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators
通讯作者：
Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators